Combo HCV Promise Attracts Ascletis To Presidio Asset
This article was originally published in The Pink Sheet Daily
Executive Summary
Ascletis will fund clinical development, manufacturing and commercialization of Presidio Pharmaceuticals’ PPI-668 in its territories, and will make undisclosed upfront, development milestone and tiered royalty payments to the U.S. venture.